May 7, 2021 10:50 AM EDT

Another failed trial for Orphazyme's 'pipeline-in-a-product' leaves shadow on drug's future

Josh Sullivan

The tumultuous ride for Orphazyme continued on Friday as the company announced that a pivotal trial for its lead drug arimoclomol failed yet again, this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Another failed trial for Orphazyme's 'pipeline-in-a-product' leaves shadow on drug's future

Josh Sullivan

Sign up to read this article for free.

Updated: CEO of UnitedHealth insurance unit shot and killed in New York in what police call ‘a brazen, targeted ...

Bluebird and Vertex's sickle cell gene therapies to kick off new Medicaid access model

Lilly beats Novo in bellwether head-to-head weight loss study

As 23andMe struggles, another genetic testing company bets on drug discovery

Moderna CEO defends pandemic prep efforts with critics set to enter Trump’s administration

Trade group tells FDA that semaglutide is not too 'complex' for compounding

An­oth­er failed tri­al for Or­p­hazyme's 'pipeline-in-a-pro­duc­t' leaves shad­ow on drug's fu­ture

Josh Sullivan

Sign up to read this article for free.

more like this

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

Mod­er­na CEO de­fends pan­dem­ic prep ef­forts with crit­ics set to en­ter Trump’s ad­min­is­tra­tion

Trade group tells FDA that semaglu­tide is not too 'com­plex' for com­pound­ing

Another failed trial for Orphazyme's 'pipeline-in-a-product' leaves shadow on drug's future

Updated: CEO of UnitedHealth insurance unit shot and killed in New York in what police call ‘a brazen, targeted ...

Bluebird and Vertex's sickle cell gene therapies to kick off new Medicaid access model

Lilly beats Novo in bellwether head-to-head weight loss study

As 23andMe struggles, another genetic testing company bets on drug discovery

Moderna CEO defends pandemic prep efforts with critics set to enter Trump’s administration

Trade group tells FDA that semaglutide is not too 'complex' for compounding